IO Biotech launches $19.5M ATM equity program with Cowen, up to $75M total

IO Biotech, Inc.

Filed prospectus supplement for at-the-market offering of common stock up to $19.5 million.
Sales agreement with Cowen and Company allows additional sales up to $75 million aggregate.
Proceeds to fund preclinical studies, clinical trials, product acquisitions, and working capital.
Cowen receives 3% commission on gross sales; shares sold through Nasdaq or other markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.